Maintenance Immunotherapy in MOGAD: Early Steroid Benefit, Dose Thresholds, and Disability Risk - Part 1
About this episode
Dr. Justin Abbatemarco and Dr. Benjamin P. Trewin discuss findings on maintenance immunotherapy in MOGAD.
In part one of this series, Dr. Justin Abbatemarco and Dr. Benjamin P. Trewin discuss the major findings from his work. Read more about this abstract on the AAN website .
People in this episode
Guests: Dr. Justin Abbatemarco, Dr. Benjamin P. Trewin
Mentioned in this episode
Organizations: American Academy of Neurology
More episodes of Neurology Minute
- Maintenance Immunotherapy in MOGAD: Early Steroid Benefit, Dose Thresholds, and Disability Risk - Part 2
- Epstein-Barr Virus Antibodies to Differentiate MS From Other Neuroinflammatory Diseases - Part 2
- Clinical Reasoning Series: A 70-Year-Old Man With Systemic Illness Related Strokes Refractory to Medical Treatment Managed With Intracranial Stent
- Epstein-Barr Virus Antibodies to Differentiate MS From Other Neuroinflammatory Diseases - Part 1
- April 20, 2026 Capitol Hill Report: Neuroscience Research in FY2027
- Navigating the Residency Application Process: Key Takeaways for Aspiring Neurologists
Explore listener stats, chart rankings, contacts and more on the Neurology Minute podcast page.